Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...
The Trump administration plans to announce a deal with pharmaceutical companies to sell discounted weight-loss drugs through ...
FDA feedback supports BiomX’s plan to advance its phage-based therapy into DFI as the next clinical indication, following the Company’s previous Phase 2 study of BX211, a phage product for the ...